Vor Bio Strengthens Clinical Leadership With Appointment of Dr. Qing Zuraw As Chief Development Officer

Vor Bio has announced the appointment of Dr. Qing Zuraw as its new Chief Development Officer, bringing over 25 years of clinical development experience in autoimmune and immunologic diseases. She steps into the role effective immediately, reinforcing Vor Bio’s leadership team as the company advances its mission to transform treatment paradigms in autoimmune care.

“Vor Bio is uniquely positioned to become a leader in autoimmune therapeutics. Having been intimately involved in the development of telitacicept in China from early clinical stages through to multiple approvals, I’m thrilled to join the talented team at Vor Bio to bring telitacicept to patients globally,” said Dr. Zuraw. 

Dr. Zuraw previously served as Chief Development Officer at RemeGen, where she played a pivotal role in the successful clinical development and regulatory approval of telitacicept in China for systemic lupus erythematosus, myasthenia gravis, and rheumatoid arthritis. She led global teams across clinical trial design, regulatory strategy, and execution, and worked closely with health authorities including the FDA, EMA, and China’s CDE.

“We are delighted to welcome Qing to Vor Bio at a critical time for the company. Her deep and diverse clinical development expertise across autoimmune and immunological diseases and with telitacicept will be invaluable as we execute on our late-stage programs. Qing’s ability to lead high-performing clinical organizations will be instrumental as we drive forward our global development programs, particularly in the U.S,”said Jean-Paul Kress, M.D., Chief Executive Officer and Chairman of the Board. 

Her earlier roles span leadership positions at global pharma companies including Janssen, Teva, Biogen, and Akebia. Dr. Zuraw has contributed to multiple successful FDA approvals, including the biologic Guselkumab for psoriatic arthritis. Her addition to Vor Bio strengthens its clinical development expertise as the company accelerates novel therapies for autoimmune conditions.